Larimar Therapeutics (STU:ZA71) Research & Development: €130.90 Mil (TTM As of Mar. 2026)


STU:ZA71 Larimar Therapeutics Inc STU:ZA71
34 GF Score
Price €3.16
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics Research & Development?

Larimar Therapeutics STU:ZA71 +3.27% 34 Research & Development is €130.90 Mil as of Mar. 2026. GuruFocus rates STU:ZA71 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Larimar Therapeutics's Research & Development for the three months ended in Mar. 2026 was €21.65 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €130.90 Mil.

Larimar Therapeutics  (STU:ZA71) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Larimar Therapeutics Research & Development Related Terms

Larimar Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Larimar Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Larimar Therapeutics Research & Development Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 33.98 22.89 25.37 69.98 131.71

Larimar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.56 20.26 38.28 50.71 21.65
STU:ZA71
34GF Score
Larimar Therapeutics Inc STU:ZA71
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Larimar Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €130.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €130.90 Mil mean?
Larimar Therapeutics (STU:ZA71) has a Research & Development of €130.90 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Larimar Therapeutics and its competitors.
Is Larimar Therapeutics' Research & Development too high?
Larimar Therapeutics' current Research & Development is €130.90 Mil. Overall, Larimar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Research & Development compare to GLSI and RGNX?
Larimar Therapeutics' Research & Development of €130.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Larimar Therapeutics and its competitors. Larimar Therapeutics's current Research & Development is €130.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (STU:ZA71) has a current Research & Development of €130.90 Mil. The current Research & Development is €130.90 Mil. Larimar Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Larimar Therapeutics (STU:ZA71), the current Research & Development is €130.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Larimar Therapeutics Business Description

Other Exchanges LRMR:USAZA71:Germany
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score

Get the complete analysis for STU:ZA71

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.16
Price